Short answer
Krystal Biotech, Inc. (KRYS) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $98M (up 16.6% year over year) with net income of $79M.
Q3 2025 key financials · XBRL
- Revenue
- $98M
- +16.6% YoY · +1.8% QoQ
- Net income
- $79M
- +192.0% YoY · +107.0% QoQ
- Operating margin
- 42.5%
- EPS (diluted)
- $2.66
- +192.3% YoY · +107.8% QoQ
Source: XBRL data from the Krystal Biotech, Inc. (KRYS) Q3 2025 10-Q on SEC EDGAR. USD.
Krystal Biotech, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA label update for VYJUVEK in Sep 2025 expands treatment to birth and allows patient/caregiver administration at home, increasing compliance complexity
- Material update in clinical risk: Phase 3 IOLITE study for KB803 ocular treatment ongoing with decentralized home dosing; enrollment expected complete by year end
- Impactful regulatory risk: FDA granted platform technology designation to KB801 HSV-1 vector in Oct 2025, enabling streamlined drug development and review pathways
- Operational risk: Pricing negotiations for VYJUVEK in Germany and France expected through H2 2026, impacting near-term European revenue growth and market entry timing
- Financial risk: Net product revenue $97.8M Q3 2025 up 17% YoY; gross margin 96% with cost of goods sold down 36% YoY reflects strong profitability and efficient manufacturing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Krystal Biotech, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.